WO2021098679A1 - Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 - Google Patents
Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 Download PDFInfo
- Publication number
- WO2021098679A1 WO2021098679A1 PCT/CN2020/129350 CN2020129350W WO2021098679A1 WO 2021098679 A1 WO2021098679 A1 WO 2021098679A1 CN 2020129350 W CN2020129350 W CN 2020129350W WO 2021098679 A1 WO2021098679 A1 WO 2021098679A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- tumor
- fak inhibitor
- therapeutic agent
- paclitaxel
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 120
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 229940124783 FAK inhibitor Drugs 0.000 title claims abstract description 32
- 230000035772 mutation Effects 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 101150073096 NRAS gene Proteins 0.000 title description 3
- ULMMVBPTWVRPSI-UHFFFAOYSA-N 2-fluoro-5-methoxy-4-[[4-[(2-methyl-3-oxo-1h-isoindol-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-n-(1-methylpiperidin-4-yl)benzamide Chemical group FC=1C=C(NC=2N=C(OC=3C=4C(=O)N(C)CC=4C=CC=3)C(=CN=2)C(F)(F)F)C(OC)=CC=1C(=O)NC1CCN(C)CC1 ULMMVBPTWVRPSI-UHFFFAOYSA-N 0.000 claims abstract description 69
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 102100039788 GTPase NRas Human genes 0.000 claims abstract description 26
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 24
- IGUBBWJDMLCRIK-UHFFFAOYSA-N 2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=CC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1C(F)(F)F IGUBBWJDMLCRIK-UHFFFAOYSA-N 0.000 claims abstract description 7
- BVAHPPKGOOJSPU-UHFFFAOYSA-N 2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC=C1NC1=CC(NC=2N(N=C(C)C=2)C(C)C)=NC=C1Cl BVAHPPKGOOJSPU-UHFFFAOYSA-N 0.000 claims abstract description 7
- LKLWTLXTOVZFAE-UHFFFAOYSA-N benzenesulfonic acid;n-methyl-n-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.CS(=O)(=O)N(C)C1=NC=CC=C1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F LKLWTLXTOVZFAE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229950008937 defactinib Drugs 0.000 claims abstract description 7
- FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 claims abstract description 7
- -1 mercaptothioprine Chemical compound 0.000 claims description 91
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 63
- 229940124597 therapeutic agent Drugs 0.000 claims description 43
- 229930012538 Paclitaxel Natural products 0.000 claims description 31
- 229960001592 paclitaxel Drugs 0.000 claims description 31
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 31
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 24
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 21
- 206010009944 Colon cancer Diseases 0.000 claims description 21
- 229960003603 decitabine Drugs 0.000 claims description 21
- 229960003668 docetaxel Drugs 0.000 claims description 21
- 229960002621 pembrolizumab Drugs 0.000 claims description 21
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 20
- 229960003048 vinblastine Drugs 0.000 claims description 20
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 20
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 18
- 229940009456 adriamycin Drugs 0.000 claims description 18
- 201000004101 esophageal cancer Diseases 0.000 claims description 18
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 17
- 229960004679 doxorubicin Drugs 0.000 claims description 17
- 201000001441 melanoma Diseases 0.000 claims description 17
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 16
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 14
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 14
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 14
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 14
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 14
- 229960003852 atezolizumab Drugs 0.000 claims description 14
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 14
- 229960004562 carboplatin Drugs 0.000 claims description 14
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 14
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 14
- 229960004316 cisplatin Drugs 0.000 claims description 14
- 229960005277 gemcitabine Drugs 0.000 claims description 14
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 14
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 14
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 14
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 14
- 229960001756 oxaliplatin Drugs 0.000 claims description 14
- 201000002510 thyroid cancer Diseases 0.000 claims description 14
- 229960000303 topotecan Drugs 0.000 claims description 14
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 229960001611 alectinib Drugs 0.000 claims description 10
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 claims description 10
- 229960004066 trametinib Drugs 0.000 claims description 10
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 9
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 9
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 8
- 238000002659 cell therapy Methods 0.000 claims description 8
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 8
- 229960001428 mercaptopurine Drugs 0.000 claims description 8
- 238000001959 radiotherapy Methods 0.000 claims description 8
- 229940095064 tartrate Drugs 0.000 claims description 8
- 229950007123 tislelizumab Drugs 0.000 claims description 8
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 7
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 7
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims description 7
- GXMBXAFPYICUDZ-UHFFFAOYSA-N 2,2-dichloro-n-methylethanamine Chemical compound CNCC(Cl)Cl GXMBXAFPYICUDZ-UHFFFAOYSA-N 0.000 claims description 7
- NUIGWTHJDCDLPS-UHFFFAOYSA-N 2-(sulfanylamino)-3,7-dihydropurin-6-one Chemical compound N1C(NS)=NC(=O)C2=C1N=CN2 NUIGWTHJDCDLPS-UHFFFAOYSA-N 0.000 claims description 7
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 7
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 7
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 7
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims description 7
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 7
- 201000003076 Angiosarcoma Diseases 0.000 claims description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 7
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 108010006654 Bleomycin Proteins 0.000 claims description 7
- 241000219198 Brassica Species 0.000 claims description 7
- 235000003351 Brassica cretica Nutrition 0.000 claims description 7
- 235000003343 Brassica rupestris Nutrition 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 7
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims description 7
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 7
- 108010092160 Dactinomycin Proteins 0.000 claims description 7
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 7
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 7
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 7
- 208000017604 Hodgkin disease Diseases 0.000 claims description 7
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 7
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 7
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 7
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 7
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 7
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 7
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 7
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 7
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 7
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 7
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 7
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 7
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 7
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 7
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 7
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 7
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 7
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 7
- 206010029260 Neuroblastoma Diseases 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 7
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 7
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 7
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 7
- 229960000853 abiraterone Drugs 0.000 claims description 7
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 7
- 229960001686 afatinib Drugs 0.000 claims description 7
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 7
- 229960002833 aflibercept Drugs 0.000 claims description 7
- 108010081667 aflibercept Proteins 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229960003982 apatinib Drugs 0.000 claims description 7
- 229960001230 asparagine Drugs 0.000 claims description 7
- 235000009582 asparagine Nutrition 0.000 claims description 7
- 229960003005 axitinib Drugs 0.000 claims description 7
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 7
- 229960002756 azacitidine Drugs 0.000 claims description 7
- 108700004675 bleomycetin Proteins 0.000 claims description 7
- 229960001561 bleomycin Drugs 0.000 claims description 7
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 7
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 claims description 7
- 229960003736 bosutinib Drugs 0.000 claims description 7
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 7
- 229950004272 brigatinib Drugs 0.000 claims description 7
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 7
- 229940127093 camptothecin Drugs 0.000 claims description 7
- 229960003261 carmofur Drugs 0.000 claims description 7
- 229960005243 carmustine Drugs 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 229960005395 cetuximab Drugs 0.000 claims description 7
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 229960005061 crizotinib Drugs 0.000 claims description 7
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 7
- 229960004397 cyclophosphamide Drugs 0.000 claims description 7
- 229960000684 cytarabine Drugs 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 229960002465 dabrafenib Drugs 0.000 claims description 7
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 7
- 229960003901 dacarbazine Drugs 0.000 claims description 7
- 229960000640 dactinomycin Drugs 0.000 claims description 7
- 229960002448 dasatinib Drugs 0.000 claims description 7
- 229960000975 daunorubicin Drugs 0.000 claims description 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 7
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 7
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 7
- 229960004671 enzalutamide Drugs 0.000 claims description 7
- 229960001904 epirubicin Drugs 0.000 claims description 7
- 229930013356 epothilone Natural products 0.000 claims description 7
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 7
- 229960001433 erlotinib Drugs 0.000 claims description 7
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 7
- 210000003236 esophagogastric junction Anatomy 0.000 claims description 7
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 7
- 229960005420 etoposide Drugs 0.000 claims description 7
- 229960005167 everolimus Drugs 0.000 claims description 7
- 229960000390 fludarabine Drugs 0.000 claims description 7
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 7
- 229960002949 fluorouracil Drugs 0.000 claims description 7
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 7
- 229960002074 flutamide Drugs 0.000 claims description 7
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 7
- 229960004421 formestane Drugs 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 229960002584 gefitinib Drugs 0.000 claims description 7
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 229950007440 icotinib Drugs 0.000 claims description 7
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims description 7
- 229960000908 idarubicin Drugs 0.000 claims description 7
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 7
- 229960001101 ifosfamide Drugs 0.000 claims description 7
- 229960002411 imatinib Drugs 0.000 claims description 7
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 7
- 239000002955 immunomodulating agent Substances 0.000 claims description 7
- 229960004768 irinotecan Drugs 0.000 claims description 7
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 7
- 229960004942 lenalidomide Drugs 0.000 claims description 7
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 7
- 206010024627 liposarcoma Diseases 0.000 claims description 7
- 229960002247 lomustine Drugs 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 229960000485 methotrexate Drugs 0.000 claims description 7
- 235000010460 mustard Nutrition 0.000 claims description 7
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims description 7
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 7
- 229960001420 nimustine Drugs 0.000 claims description 7
- 229960003301 nivolumab Drugs 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 201000006958 oropharynx cancer Diseases 0.000 claims description 7
- 229960003278 osimertinib Drugs 0.000 claims description 7
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 229960005079 pemetrexed Drugs 0.000 claims description 7
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 7
- 229960002087 pertuzumab Drugs 0.000 claims description 7
- 229960000624 procarbazine Drugs 0.000 claims description 7
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 7
- 229960004432 raltitrexed Drugs 0.000 claims description 7
- 206010038038 rectal cancer Diseases 0.000 claims description 7
- 201000001275 rectum cancer Diseases 0.000 claims description 7
- 229960004836 regorafenib Drugs 0.000 claims description 7
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 7
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 7
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 7
- 229960003452 romidepsin Drugs 0.000 claims description 7
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 7
- 108010091666 romidepsin Proteins 0.000 claims description 7
- 201000000849 skin cancer Diseases 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- 229960003787 sorafenib Drugs 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 229960001796 sunitinib Drugs 0.000 claims description 7
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 7
- 229960001603 tamoxifen Drugs 0.000 claims description 7
- 229960001674 tegafur Drugs 0.000 claims description 7
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 7
- 229960004964 temozolomide Drugs 0.000 claims description 7
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 7
- 229960001278 teniposide Drugs 0.000 claims description 7
- 229960000575 trastuzumab Drugs 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 229960000653 valrubicin Drugs 0.000 claims description 7
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims description 7
- 229960000241 vandetanib Drugs 0.000 claims description 7
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 7
- 229960004528 vincristine Drugs 0.000 claims description 7
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 7
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 7
- 229960004355 vindesine Drugs 0.000 claims description 7
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 7
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 7
- 229960000237 vorinostat Drugs 0.000 claims description 7
- KCEHUPIXDRDKQS-VKHMYHEASA-N (2s)-5-amino-2-hydrazinyl-5-oxopentanoic acid Chemical compound NN[C@H](C(O)=O)CCC(N)=O KCEHUPIXDRDKQS-VKHMYHEASA-N 0.000 claims description 6
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 6
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 6
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 6
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 6
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 6
- 229960000397 bevacizumab Drugs 0.000 claims description 6
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims description 6
- 201000003115 germ cell cancer Diseases 0.000 claims description 6
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 229960001156 mitoxantrone Drugs 0.000 claims description 6
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 5
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 5
- 229960002932 anastrozole Drugs 0.000 claims description 5
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 claims description 5
- 229950004810 atamestane Drugs 0.000 claims description 5
- 229960001602 ceritinib Drugs 0.000 claims description 5
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 5
- 229960004630 chlorambucil Drugs 0.000 claims description 5
- 229960001507 ibrutinib Drugs 0.000 claims description 5
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 5
- 229960002066 vinorelbine Drugs 0.000 claims description 5
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 5
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 4
- UXUZARPLRQRNNX-DXTOWSMRSA-N 2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F UXUZARPLRQRNNX-DXTOWSMRSA-N 0.000 claims description 4
- 102000015790 Asparaginase Human genes 0.000 claims description 4
- 108010024976 Asparaginase Proteins 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- 229960003272 asparaginase Drugs 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 4
- 229960000997 bicalutamide Drugs 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 229960004117 capecitabine Drugs 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 4
- 229960003881 letrozole Drugs 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 3
- 229960001292 cabozantinib Drugs 0.000 claims 3
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 3
- 229960001972 panitumumab Drugs 0.000 claims 3
- 229940063683 taxotere Drugs 0.000 claims 3
- 239000010975 amethyst Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 229910000951 Aluminide Inorganic materials 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- DNYGXMICFMACRA-XHEDQWPISA-N Gentamicin C2b Chemical compound O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N DNYGXMICFMACRA-XHEDQWPISA-N 0.000 claims 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 1
- 229940076134 benzene Drugs 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 229960003648 ixazomib Drugs 0.000 claims 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 1
- 229960001221 pirarubicin Drugs 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 49
- 230000004614 tumor growth Effects 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 230000037396 body weight Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 10
- 102000000646 Interleukin-3 Human genes 0.000 description 9
- 108010002386 Interleukin-3 Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 102200124919 rs121913237 Human genes 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 6
- 231100000590 oncogenic Toxicity 0.000 description 6
- 230000002246 oncogenic effect Effects 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100030708 GTPase KRas Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 102100029974 GTPase HRas Human genes 0.000 description 4
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229950010203 nimotuzumab Drugs 0.000 description 4
- 238000010972 statistical evaluation Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 3
- 229930192392 Mitomycin Natural products 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 238000011786 NMRI nude mouse Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002122 leukaemogenic effect Effects 0.000 description 2
- 201000001439 malignant skin fibrous histiocytoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000019448 vaginal melanoma Diseases 0.000 description 2
- IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150041972 CDKN2A gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 101150046722 idh1 gene Proteins 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 description 1
- 108700042657 p16 Genes Proteins 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102220197775 rs1057519695 Human genes 0.000 description 1
- 102200006648 rs28933406 Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention belongs to the field of medicinal chemistry. Specifically, the present invention relates to the use of a FAK inhibitor in the preparation of a medicament for the treatment of tumors with NRAS mutations.
- FAK also known as protein tyrosine kinase 2 (PTK2)
- PTK2 protein tyrosine kinase 2
- FAK plays an important role in mediating integrin and growth factor signals to regulate tumor cell invasion, proliferation and survival.
- FAK is widely expressed and evolutionarily conserved.
- Studies in the past two decades have shown that FAK is overexpressed in a variety of solid tumors, and the expression level is negatively correlated with tumor prognosis.
- Recent studies have also shown that FAK plays an important role in regulating the tumor microenvironment, suggesting that FAK plays an important role in the adaptive drug resistance of immunotherapy and anti-tumor therapy. Both in vitro and in vivo preclinical studies have shown that blocking FAK has anti-tumor effects.
- the inhibitory activity of FAK inhibitors on tumors varies greatly.
- BI853520 is a FAK inhibitor. BI853520 exhibits different anti-tumor activities in CDX (human tumor cell line transplanted mice) models of 37 different tumor types, and its TGI (tumor growth inhibition) span ranges from 0-107 % Varies. How to use it more targeted to inhibit tumor growth is an urgent technical problem in this field.
- the present invention provides a use of a FAK inhibitor in the preparation of a medicament for treating tumors with NRAS mutations.
- the FAK inhibitor is BI853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.
- the FAK inhibitor is BI853520 or a pharmaceutically acceptable salt thereof, especially BI853520 tartrate.
- the BI 853520 has the following structure:
- the drug is used in combination with an effective amount of a second therapeutic agent.
- the drug is used in combination with radiotherapy or cell therapy.
- the tumor is Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid Leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, Angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, skin cancer, germ cell Cancer, nasopharyngeal cancer, oropharyngeal
- the second therapeutic agent is selected from one or more of chemotherapeutic agents, targeted therapeutic agents and immunotherapeutic agents.
- the second therapeutic agent is selected from the group consisting of nimustine, carmustine, lomustine, temozolomide, cyclophosphamide, ifosfamide, glyphosyl mustard, deoxyfluoroguanosine, poly Cifluguanidine, fluorouracil, mercaptopurine, mercaptothioprine, mercaptoguanine, fluguanosine, tegafur, gemcitabine, decitabine, carmofur, hydroxyurea, methotrexate, ufludine, calcin Pecitabine, Acitabine, Cetepa, Actinomycin D, Adriamycin, Liposome Adriamycin, Daunorubicin, Epirubicin, Mitomycin, Pingyangmycin, Pirubicin Picin, valrubicin, idarubicin, irinotecan, triapexine, camptothecin, hydroxycamptothecin, topotecan, vin
- the second therapeutic agent is selected from the group consisting of decitabine, gemcitabine, cisplatin, carboplatin, oxaliplatin, doxorubicin, liposomal doxorubicin, paclitaxel, docetaxel, trime Tinib, bimetinib, cobitinib, devaluzumab, atezolizumab, sintilizumab, teriprizumab, carrelizumab, tislelizumab , Nivolumab, Pembrolizumab.
- the second therapeutic agent docetaxel, liposomal adriamycin, cobitinib, pembrolizumab, and decitabine;
- the second therapeutic agent is cobitinib.
- the present invention also provides a method for treating tumors with NRAS mutations, which comprises administering an effective amount of FAK inhibitor to the individual.
- the FAK inhibitor is BI853520 or defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof, preferably BI853520 or a pharmaceutically acceptable salt thereof, especially BI853520 tartrate.
- it further comprises administering to the individual an effective amount of a second therapeutic agent.
- it further includes radiotherapy or cell therapy.
- the tumor is Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid Leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, Angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, skin cancer, germ cell Cancer, nasopharyngeal cancer, oropharyngeal
- the second therapeutic agent is selected from one or more of chemotherapeutic agents, targeted therapeutic agents and immunotherapeutic agents.
- the second therapeutic agent is selected from the group consisting of nimustine, carmustine, lomustine, temozolomide, cyclophosphamide, ifosfamide, glyphosyl mustard, deoxyfluoroguanosine, poly Cifluguanidine, fluorouracil, mercaptopurine, mercaptothioprine, mercaptoguanine, fluguanosine, tegafur, gemcitabine, decitabine, carmofur, hydroxyurea, methotrexate, ufludine, calcin Pecitabine, Acitabine, Cetepa, Actinomycin D, Adriamycin, Liposome Adriamycin, Daunorubicin, Epirubicin, Mitomycin, Pingyangmycin, Pirubicin Picin, valrubicin, idarubicin, irinotecan, triapexine, camptothecin, hydroxycamptothecin, topotecan, vin
- the second therapeutic agent is selected from the group consisting of decitabine, gemcitabine, cisplatin, carboplatin, oxaliplatin, doxorubicin, liposomal doxorubicin, paclitaxel, docetaxel, trime Tinib, bimetinib, cobitinib, devaluzumab, atezolizumab, sintilizumab, teriprizumab, carrelizumab, tislelizumab , Nivolumab, Pembrolizumab.
- the second therapeutic agent docetaxel, liposomal adriamycin, cobitinib, pembrolizumab, and decitabine;
- the second therapeutic agent is cobitinib.
- the second therapeutic agent is administered synchronously, alternately or sequentially.
- the FAK inhibitor and radiotherapy or cell therapy are performed synchronously, alternately or sequentially.
- the present invention provides a FAK inhibitor for treating tumors with NRAS mutations.
- the FAK inhibitor is BI853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof, preferably BI853520 or a pharmaceutically acceptable salt thereof, especially BI853520 tartrate.
- it is further used in combination with an effective amount of a second therapeutic agent.
- the tumor is Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid Leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, Angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, thymic cancer, pancreatic cancer, endometrial cancer, cervical cancer, melanoma, skin cancer, germ cell Cancer, nasopharyngeal cancer, oropharyngeal
- the second therapeutic agent is selected from one or more of chemotherapeutic agents, targeted therapeutic agents and immunotherapeutic agents.
- the second therapeutic agent is selected from the group consisting of nimustine, carmustine, lomustine, temozolomide, cyclophosphamide, ifosfamide, glyphosyl mustard, deoxyfluoroguanosine, poly Cifluguanidine, fluorouracil, mercaptopurine, mercaptothioprine, mercaptoguanine, fluguanosine, tegafur, gemcitabine, decitabine, carmofur, hydroxyurea, methotrexate, ufludine, calcin Pecitabine, Acitabine, Cetepa, Actinomycin D, Adriamycin, Liposome Adriamycin, Daunorubicin, Epirubicin, Mitomycin, Pingyangmycin, Pirubicin Picin, valrubicin, idarubicin, irinotecan, triapexine, camptothecin, hydroxycamptothecin, topotecan, vin
- the second therapeutic agent is selected from the group consisting of decitabine, gemcitabine, cisplatin, carboplatin, oxaliplatin, doxorubicin, liposomal doxorubicin, paclitaxel, docetaxel, trime Tinib, bimetinib, cobitinib, devaluzumab, atezolizumab, sintilizumab, teriprizumab, carrelizumab, tislelizumab , Nivolumab, Pembrolizumab.
- the second therapeutic agent docetaxel, liposomal adriamycin, cobitinib, pembrolizumab, and decitabine;
- the second therapeutic agent is cobitinib.
- FAK inhibitor refers to an effective inhibitor of FAK, which may be suitable for mammals, especially humans.
- NRAS refers to an oncogene, a member of the RAS oncogene family, which also includes two other genes: KRAS and HRAS. These genes play an important role in cell division, cell differentiation and apoptosis.
- NRAS mutation means that when a pathogenic mutation occurs in the NRAS gene, the N-Ras protein encoded by it will be in a state of continuous activation, leading to uncontrolled cell proliferation and the formation of tumors.
- treatment refers to the administration of one or more drug substances (especially the FAK inhibitors described herein, especially BI853520 or its pharmaceutically acceptable The salt) is used to cure, alleviate, alleviate, change, cure, improve, improve or affect the disease or the symptoms of the disease.
- the disease is tumor or cancer.
- the disease is a cancer or tumor in which NRAS mutations occur.
- tumor refers to the abnormal pathological changes in which the cells of the local tissue lose their normal regulation of their growth at the gene level under the action of various tumor-causing factors, resulting in abnormal clonal proliferation.
- examples include, but are not limited to: Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, myelodysplastic syndrome, acute lymphocytic leukemia, acute myeloid Leukemia, chronic myeloid leukemia, thyroid cancer, glioma, colon cancer, rectal cancer, colorectal cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, liposarcoma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, Angiosarcoma, neuroblastoma, renal cell carcinoma, head and neck cancer, gastric cancer, esophageal
- the term "individual” as used herein refers to mammals and non-mammals. Mammal refers to any member of the mammalian class, which includes but is not limited to: humans; non-human primates, such as chimpanzees and other apes and monkey species; farm animals, such as cows, horses, sheep, goats, and pigs; Domestic animals, such as rabbits, dogs, and cats; laboratory animals, including rodents, such as rats, mice, and guinea pigs; and so on. Examples of non-mammals include but are not limited to birds and the like.
- the term "individual” does not limit a specific age or gender. In some embodiments, the individual is a human.
- pharmaceutically acceptable refers to non-toxic, biologically tolerable, and suitable for administration to an individual.
- pharmaceutically acceptable salt refers to a non-toxic, biologically tolerable acid addition salt of BI853520 suitable for administration to an individual, including but not limited to: the acid formed by BI853520 and inorganic acid Addition salts, such as hydrochloride, hydrobromide, carbonate, bicarbonate, phosphate, sulfate, sulfite, nitrate, etc.; and acid addition salts formed by BI853520 with organic acids, such as methyl Acid salt, acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxy Ethyl sulfonate, benzoate, salicylate, stearate, and salt formed with alkane dicarboxylic acid of the formula HOOC-(CH 2 ) n -COOH (wherein n is 0-4), etc.
- Addition salts such as hydrochlor
- a pharmaceutically acceptable acid addition salt can be obtained by dissolving the free base in a suitable solvent and treating the solution with an acid in accordance with the conventional operation for preparing an acid addition salt from a basic compound.
- Those skilled in the art can determine various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable acid addition salts without undue experimentation.
- the term "effective amount” as used herein refers to an amount generally sufficient to produce a beneficial effect on an individual.
- Conventional methods such as modeling, dose escalation studies, or clinical trials
- conventional influencing factors such as the method of administration, the pharmacokinetics of the compound, the severity and course of the disease, the individual's medical history, the individual's health, the individual The degree of response to the drug, etc.
- second therapeutic agent refers to one or more drug substances used to prevent and/or treat diseases.
- the second therapeutic agent is selected from one or more of chemotherapeutic agents, targeted therapeutic agents and immunotherapeutic agents.
- the second therapeutic agent is selected from the group consisting of nimustine, carmustine, lomustine, temozolomide, cyclophosphamide, ifosfamide, glycosyl mustard, deoxyfluoguanosine , Doxyfluguanidine, Fluorouracil, Mercaptopurine, Mercaptopurine, Mercaptoguanine, Fluguanosine, Tegafur, Gemcitabine, Decitabine, Carmofur, Hydroxyurea, Methotrexate, Ufludine , Capecitabine, amcitabine, cetepa, actinomycin D, doxorubicin, liposomal doxorubicin, daunorubicin, epirubicin, miomycin,
- the second therapeutic agent is selected from the group consisting of decitabine, gemcitabine, cisplatin, carboplatin, oxaliplatin, doxorubicin, liposomal doxorubicin, paclitaxel, docetaxel, and Trimex Tinib, bimetinib, cobitinib, devaluzumab, atezolizumab, sintilizumab, teriprizumab, carrelizumab, tislelizumab , Nivolumab, Pembrolizumab.
- the second therapeutic agent docetaxel, liposomal adriamycin, cobitinib, pembrolizumab, decitabine; optionally, the second therapeutic agent is a test Bitinib.
- the drug substance selected from the second therapeutic agent will be slightly different due to different translations, but they refer to a drug substance, for example: Cobimetinib (also known as Cobimetinib) .
- inhibitor refers to a reduction in the baseline activity of a biological activity or process.
- Figure 1 shows the effect of IL-3 on the anti-proliferative effect of BI 853520 in the Ba/F3-NRAS G12D cell line.
- IC 50 increase more than 4 times.
- Figure 3 shows the HT-1080 tumor growth kinetics.
- the tumor volume of treated BI 853520 6mg / kg median of 322mm 3 BI 853520 treatment to 12.5mg / kg of tumor volume
- the median was 149 mm 3
- the median tumor volume treated with 25 mg/kg BI 853520 was 15 mm 3
- the median tumor volume treated with 50 mg/kg BI 853520 was 322 mm 3 .
- Figure 4 shows the KYSE-270 tumor growth kinetics, which shows that the median tumor volume of the control group increased from 179 mm 3 to 1032 mm 3 , compared with the control group, the tumor volume treated with 50 mg/kg BI 853520 per day
- the median decreased from 175mm 3 to 126mm 3 , once a week treatment with 10mg/kg paclitaxel had no effect on tumor growth, the median tumor volume increased from 190mm 3 to 1033mm 3 , once a day with 50mg/kg BI 853520 and weekly a combination therapy 10mg / kg paclitaxel, a significant delay of tumor growth, tumor volume median dropped from 173mm 3 to 87mm 3.
- Figure 5 shows the change in body weight. It showed that the median weight of animals in the control group decreased by 10.3%. Compared with the control group, the median weight of animals treated with 50 mg/kg BI 853520 per day increased by 2.8%, and paclitaxel was used once a week at 10 mg/kg. The median weight of the treated animals decreased by 9.7%, and the combined treatment of 50 mg/kg BI 853520 once a day and 10 mg/kg paclitaxel once a week increased the median weight of the animals by 3.5%.
- Figure 6 shows GAK tumor growth kinetics. It shows that in the GAK model, compared with the control group, daily BI 853520 treatment delayed tumor growth.
- Figure 7 shows HMVII tumor growth kinetics. It shows that in the HMVII model, compared with the control group, daily BI 853520 treatment delayed tumor growth.
- Example I The correlation between BI853520's anti-tumor effect and NRAS
- the Ba/F3 cell line was obtained from ATCC in 2009, and according to Zhang X, Ren R. Bcr-abl, efficiently induce a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor for novel model: A Chronic myelogenous leukemia. Blood., 1998, 92: 3829-40.
- the growth factor-dependent BA/F3 cells were cultured in RPMI 1640 containing 10% FBS, and supplemented with 15% WEHI-3 conditioned medium or recombinant IL-3 (Roche) as the source of IL-3, the final concentration was 1ng/ ml.
- BI853520 Synthesized according to the method in patent WO2010058032.
- NRAS G12D transfected Ba/F3 (Ba/F3-N) or KRAS G12D transfected Ba/F3 (Ba/F3-N) cells were seeded to 96 cells at a density of 5000 cells per well.
- BI853520 was diluted 3-fold with RPMI 1640 at 9 points, and added according to the volume of each well, starting at 10 ⁇ mol/L, reaching a 3-fold concentration gradient (final solvent concentration ⁇ 1/1000).
- Ba/F3 is a cell line derived from murine bone marrow that depends on IL-3 for survival and proliferation. It has been successfully used in the high-throughput analysis of kinase drug discovery.
- NRAS G12D oncogenic NRAS
- Figure 1 and Table 1 show the anti-proliferative effect of BI853520 on the Ba/F3-NRAS G12D cell line, with an IC 50 value of 3.4 ⁇ M. The IC 50 increased by more than 4 times after IL-3 was added, indicating that the inhibitory effect was related to NRAS.
- Table 1 The effect of adding IL-3 on the anti-proliferative effect of BI853520 in Ba/F3-NRAS G12D cell line
- Example 2 The effect of BI853520 in a mouse model of human fibrosarcoma (cell line HT-1080)
- BI 853520 50mg/kg, 25mg/kg, 12.5mg/kg, 6mg/kg,
- Evaluation of treatment outcome is based on the absolute volume of a single tumor
- Tolerance is evaluated based on changes in body weight.
- BI853520 Synthesized according to the method in patent WO2010058032. The dry powder was suspended in 0.5% hydroxyethyl cellulose to reach the concentration required for each experiment. The pH of this formulation is 3.5.
- HT-1080 cells carrying NRAS, CDKN2A and IDH1 gene mutations are from ATCC (CRL-121). The cells were grown in T175 tissue culture flasks with DMEM+Glutamax supplemented with 10% heat-inactivated fetal bovine serum as the medium. The cells were cultured in humidified air at 37°C and 5% CO 2.
- mice Athymic female BomTac, approximately 6-week-old NMRI-Foxn1 nu mice were purchased from Taconic, Denmark. After arriving in the animal room, the mice adapt to the new environment for at least 3 days before being used in the experiment. These animals were kept under standard conditions (temperature 21.5 ⁇ 1.5°C and 55 ⁇ 10% humidity), with 5 groups per group. Standardize diet and provide autoclaved tap water ad libitum. Datamars T-IS 8010 FDX-B transponders implanted subcutaneously in the neck area and LabMax II fixed readers were used to identify each mouse. The cage card shows the study number, animal identification number, compound and dose level, route of administration, and the animal's dosing schedule throughout the experiment.
- HT-1080 cells were collected, centrifuged, washed by trypsin digestion and resuspended in ice-cold PBS + 1 x 10 8 cells / ml medium. Then 100 ⁇ l of cell suspension containing 1 x 10 7 cells was injected subcutaneously into the right flanks of nude mice (1 site per mouse). When the tumor formed and reached a diameter of 5-8 mm (7 days after cell injection), the mice were randomly assigned to the treatment group and the blank control group.
- BI853520 is suspended in 0.5% hydroxyethyl cellulose and administered intragastrically via a gavage needle every day, with a dosage of 10 mL/Kg.
- the mice were checked daily for abnormalities, and the body weight was measured daily. The animals were sacrificed at the end of the study (approximately two weeks after the start of the treatment); during the study, for ethical reasons, animals with tumor necrosis or tumors larger than 2000 mm 3 would be sacrificed early.
- the tumor volume and body weight parameters were statistically evaluated.
- the absolute value of the tumor volume and the percentage change in body weight (refer to the initial weight on day 1) were used.
- a non-parametric method was used to calculate the number of observations, median, minimum and maximum.
- the median tumor volume of each treatment group T and the median tumor volume of the control group C are used to calculate the TGI from day 1 to day d:
- TGI 100x[(C d -C 1 )-(T d -T 1 )]/(C d -C 1 )
- C 1 , T 1 the median tumor volume of the control group and the treatment group on the first day of the experiment
- C d , C d The median tumor volume of the control group and the treatment group at the end of the experiment on the 13th day
- a unilateral decrement wilcoxon test was used to compare each dose of the test compound with the control group.
- the reduction in tumor volume was used as a therapeutic effect, and the weight loss was used as a side effect.
- the P value of tumor volume (efficacy parameter) has been compared and adjusted many times, while the P value of body weight (tolerability parameter) has not been adjusted to avoid ignoring possible side effects.
- P-value (after adjustment) less than 0.05 is considered to show a statistically significant difference between the groups, when 0.05 ⁇ p-value ⁇ 0.10, the difference is regarded as an indicative difference.
- the software package SAS version 9.2 SAS Institute Inc., North Carolina, North Carolina, USA
- Proc StatXact version 8.0 were used for statistical evaluation.
- BI 853520 showed statistically significant anti-tumor activity at all dose levels, and regression was observed in all treatment groups; at the highest dose level, tumor volume reduction was observed in all animals. In previous studies, the highest dose taken per day was 100 mg/kg, with no limiting toxicity. Therefore, a significant therapeutic effect was obtained at a dose (6 mg/kg) that was at least 16 times lower than the MTD.
- Example 3 BI 853520 subcutaneous xenograft mouse model derived from the human esophageal cancer cell line KYSE-270 in NMRI nude mice Anti-tumor activity
- Model subcutaneously xenotransplanted human esophageal cancer cell line KYSE-270 in NMRI nude mice.
- Test compound BI853520: synthesized according to the method in patent WO2010058032.
- KYSE-270 is an esophageal cancer cell line (Public Health England, catalog number: 94072021). At 37°C, the cells were cultured in T175 tissue culture flasks containing 5% CO 2. The medium used was RPMI 1640+HAM F12 (1:1) supplemented with 2% FCS and 2mM Glutamax. Passaged at a ratio of 1:2 three times a week.
- mice Female mice (BomTac:NMRI-Foxn1 nu ) between 8 and 10 weeks old purchased from Taconic, Denmark. After arriving in the animal room, allow the mice to adapt for at least 5 days before being used in the experiment. These animals are kept under standard conditions (temperature 21.5+1.5°C, humidity 55+10%), in groups of 7 to 10. Provide standard diet and autoclaved tap water for free consumption. Subcutaneous microchips implanted under isoflurane anesthesia were used to identify each mouse. Show study number, animal identification number, compound and dose level, route of administration, and the animal's dosing schedule throughout the experiment are retained on the animal.
- BI 853520 Suspend BI 853520 in 0.5% hydroxyethylcellulose, and administer intragastrically via a gavage needle every day, the dosage is 10mL/Kg body weight.
- Paclitaxel was dissolved in saline (0.9% NaCl) and administered intravenously with a volume of 10 ml/kg body weight.
- the suspension of BI853520 can be used for up to 7 days.
- the paclitaxel solution is stored at a temperature of 6°C for a maximum of 14 days.
- the tumor volume and body weight on the 13th day were statistically evaluated. Animal number 1 (blank control group) was excluded from the statistical evaluation because of weight loss and must be euthanized as soon as possible (day 9). In the statistical analysis, the measured tumor volume was used as the target variable. The number of animals in each group, the median, minimum and maximum tumor volume were calculated. In order to quickly understand the possible treatment effects, the median tumor volume of each treatment group T and the median tumor volume of the control group C are used to calculate the TGI:
- TGI 100x[(C d -C 1 )-(T d -T 1 )]/(C d -C 1 )
- C 1 , T 1 the median tumor volume of the control group and the treatment group on the first day of the experiment
- C d , C d The median tumor volume of the control group and the treatment group at the end of the experiment on the 13th day
- the Wilcoxon test was used for comparison.
- body weight the percentage change from the initial body weight on day 1 was used as the target variable for the statistical analysis. Calculate the number of animals in each group, the median, minimum and maximum weight changes.
- the p-value of the efficacy parameter was compared and adjusted several times.
- the p-value of the tolerance parameter remains unchanged, so as not to ignore possible side effects.
- the adjusted p value less than 0.05 is considered to show a statistically significant difference between the groups, and when 0.05 ⁇ p value ⁇ 0.10, the difference is considered indicative.
- the statistical evaluation was carried out using SAS 9.4 version software package (SAS Institute Inc., Cary NC, USA).
- Table 4 TGI, tumor shrinkage and weight change in each group (day 13)
- Example 4 BI 853520's effect on tumor growth of HMVII and GAK CDX models (melanoma models with NRAS mutations) Growth inhibition
- Test compound BI853520, which was synthesized according to the method in patent WO2010058032.
- BI853520 is formulated with 0.5% hydroxyethyl cellulose (Ashland).
- the melanoma cell line GAK was purchased from JCRB cell bank, and HMVII cells were purchased from Sigma. GAK originates from the inguinal lymph nodes of patients with vaginal melanoma, while HMVII originates from primary vaginal melanoma.
- GAK and HMVII cells were cultured in tissue culture flasks containing 5% CO 2 with the medium of Ham's F12 containing 10% heat-killed FBS and Ham's F10 containing 15% FBS. All media were supplemented with 100U/mL penicillin, 100mg/mL streptomycin and 2mM GlutaMAX. All cell culture reagents were purchased from GIBCO.
- HMVII and GAK cell lines carry the NRAS mutation at position Q61.
- HMVII of NRAS Q61K and GAK of NRAS Q61L carry the NRAS mutation at position Q61.
- mice Female balb/c nude mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) about 4 weeks old. After arriving in the animal room, allow the mice to adapt to the new environment for at least 2 weeks before being used in the experiment. The animals are kept under standard conditions (temperature 21.5 ⁇ 1.5°C and 55 ⁇ 10% humidity). Provide standard diet and autoclaved tap water freely. All animal care and experimental procedures were performed in accordance with the animal care ethics guidelines approved by the Medical Ethics Committee of Beijing Cancer Hospital and Research Institute.
- HMVII and GAK cells were collected by trypsinization, centrifuged, washed and resuspended in ice-cold PBS+5% FCS. Then 100 ⁇ l of a cell suspension containing 5 ⁇ 10 6 cells was injected subcutaneously into the right flanks of nude mice (1 site per mouse). When the tumor was sufficiently established and reached a median volume of about 400-600 mm 3 , the mice were randomly allocated to the treatment group and the blank control group.
- BI 853520 is configured in 0.5% hydroxyethyl cellulose and administered intragastrically via a gavage needle every day, the dosage is 10 mL/Kg body weight.
- the tumor volume was statistically evaluated at the end of the experiment. For tumor volume, use relative values.
- TGI 100x[(C d -C 1 )-(T d -T 1 )]/(C d -C 1 )
- C 1 , T 1 the average relative tumor volume of the control group and the treatment group on the first day of the experiment
- C d , C d the average of the relative tumor volume between the control group and the treatment group at the end of the experiment on day d
- Table 5 Average tumor volume, average TGI and P value based on relative tumor volume on day 14
- BI853520 can inhibit tumor growth in CDX models of HMVII and GAK (two melanoma models with NRAS mutations).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
剂量(mg/Kg) | 给药时间表 | 体重中位数改变(%) |
对照组 | qd | -1.9 |
50 | qd | +8.3 |
25 | qd | +9.4 |
12.5 | qd | +5.7 |
6 | qd | +4.7 |
Claims (23)
- FAK抑制剂在制备用于治疗NRAS突变的肿瘤的药物中的用途。
- 如权利要求1所述的用途,其特征在于,所述FAK抑制剂为BI853520、defactinib、GSK2256098、PF-00562271、VS-4718或其药学上可接受的盐,优选为BI853520或其药学上可接受的盐,尤其是BI853520酒石酸盐。
- 如权利要求1-2中任一项所述的用途,其特征在于,所述药物和有效量的第二治疗剂联用。
- 如权利要求1-3中任一项所述的用途,其特征在于,所述药物和放疗或者细胞治疗联用。
- 如权利要求1-4中任一项所述的用途,其特征在于,所述肿瘤为霍奇金淋巴瘤、非霍奇金淋巴瘤、非小细胞肺癌、小细胞肺癌、肝细胞癌、胆管癌、骨髓增生异常综合征、急性淋巴细胞白血病、急性髓系白血病、慢性髓系白血病、甲状腺癌、神经胶质瘤、结肠癌、直肠癌、结直肠癌、卵巢癌、膀胱癌、前列腺癌、乳腺癌、脂肪肉瘤、纤维肉瘤、横纹肌肉瘤、平滑肌肉瘤、血管肉瘤、神经母细胞瘤、肾细胞癌、头颈部癌、胃癌、食管癌、胃食管结合部癌、胸腺癌、胰腺癌、子宫内膜癌、宫颈癌、黑色素瘤、皮肤癌、生殖细胞癌、鼻咽癌、口咽癌、或喉癌;进一步的所述肿瘤为急性髓系白血病、黑色素瘤、甲状腺癌、结直肠癌、食道癌、肝细胞癌、卵巢癌、纤维肉瘤和胆管癌。
- 如权利要求3所述的用途,其特征在于,所述第二治疗剂选自化疗剂、靶向治疗剂和免疫治疗剂中的一种或几种。
- 如权利要求3所述的用途,其特征在于,所述第二治疗剂选自尼莫司汀、卡莫司汀、洛莫司汀、替莫唑胺、环磷酰胺、异环磷酰胺、甘磷酰芥、去氧氟鸟苷、多西氟鸟啶、氟尿嘧啶、巯嘌呤、巯唑嘌呤、巯鸟嘌呤、氟鸟苷、替加氟、吉西他滨、地西他滨、卡莫氟、羟基脲、甲胺喋呤、优氟定、卡培他滨、安西他滨、塞替哌、放线菌素D、阿霉素、脂质体阿霉素、柔红霉素、表柔比星、细裂霉素、平阳霉素、吡柔比星、戊柔比星、伊达比星、伊立替康、三尖衫酯碱、喜树碱、羟基喜树碱、托泊替康、长春瑞宾诺维本、紫杉醇、泰索帝、拓扑替康、长春碱、长春新碱、长春地辛、长春酰胺、长春花碱、替尼泊苷、依托泊苷、揽香烯、阿他美坦、阿那曲唑、氨鲁米特、来曲唑、福美坦、甲他孕酮、他莫昔芬、门冬酰胺酚、卡铂、顺铂、达卡巴嗪、奥沙利铂、乐沙定、可铂奥沙、米托蒽醌、丙卡巴肼、多西他赛、吉非替尼、厄洛替尼、埃克替尼、阿法替尼、奥希替尼、克唑替尼、色瑞替尼、艾乐替尼、拉帕替尼、依维莫司、帕博西尼、瑞博西尼、阿帕替尼、瑞戈非尼、索拉菲尼、舒尼替尼、替西罗莫司、乐伐替尼、帕唑替尼、阿雷替尼、阿希替尼、卡博替尼、曲美替尼、比美替尼、维罗非尼、达拉非尼、卡比替尼、凡德他尼、硼替佐米、帕布昔利布、来那度胺、伊沙佐米、伊马替尼、达沙替尼、博舒替尼、帕纳替尼、伊布替尼、艾代拉利司、贝利司他、罗米 地辛、伏立诺他、奥拉帕尼、尼拉帕利、狄诺赛麦、维莫德吉、索尼德吉、鲁卡帕尼、布加替尼、比卡鲁胺、恩杂鲁胺、阿比特龙、阿贝西尼、阿帕他胺、阿柏西普、阿扎胞苷、博莱霉素、苯丁酸氮芥、阿糖胞苷、天冬酰胺酶、埃坡霉素、氟达拉滨、氟他胺、双氯乙基甲胺、帕利他塞、培美曲塞、雷替曲塞、耐昔妥珠单抗、贝伐珠单抗、雷莫芦单抗、Ado-曲妥珠单抗、帕托珠单抗、西妥昔单抗、帕尼单抗、阿利库单抗、德瓦鲁单抗、尼妥珠单抗、达雷木单抗、阿特珠单抗、信迪利单抗、特瑞普利单抗、卡瑞利珠单抗、替雷利珠单抗、德瓦鲁单抗、纳武利尤单抗、帕博利珠单抗中的一种或几种;进一步的选自地西他滨、吉西他滨、顺铂、卡铂、奥沙利铂、阿霉素、脂质体阿霉素、紫杉醇、多西他赛、曲美替尼、比美替尼、考比替尼、德瓦鲁单抗、阿特珠单抗、信迪利单抗、特瑞普利单抗、卡瑞利珠单抗、替雷利珠单抗、纳武利尤单抗、帕博利珠单抗;更进一步的选自多西他赛、脂质体阿霉素、考比替尼、帕博利珠单抗、地西他滨;更进一步的选自考比替尼。
- 一种治疗发生NRAS突变的肿瘤的方法,其包括向个体施用有效量的FAK抑制剂。
- 如权利要求8所述的方法,其特征在于,所述FAK抑制剂为BI853520、defactinib、GSK2256098、PF-00562271、VS-4718或其药学上可接受的盐,优选为BI853520或其药学上可接受的盐,尤其是BI853520酒石酸盐。
- 如权利要求8-9中任一项所述的方法,其特征在于,其进一步包括向个体施用有效量的第二治疗剂。
- 如权利要求8-10中任一项所述的方法,其特征在于,其进一步包括放疗或者细胞治疗。
- 如权利要求8所述的方法,其特征在于,所述肿瘤为为霍奇金淋巴瘤、非霍奇金淋巴瘤、非小细胞肺癌、小细胞肺癌、肝细胞癌、胆管癌、骨髓增生异常综合征、急性淋巴细胞白血病、急性髓系白血病、慢性髓系白血病、甲状腺癌、神经胶质瘤、结肠癌、直肠癌、结直肠癌、卵巢癌、膀胱癌、前列腺癌、乳腺癌、脂肪肉瘤、纤维肉瘤、横纹肌肉瘤、平滑肌肉瘤、血管肉瘤、神经母细胞瘤、肾细胞癌、头颈部癌、胃癌、食管癌、胃食管结合部癌、胸腺癌、胰腺癌、子宫内膜癌、宫颈癌、黑色素瘤、皮肤癌、生殖细胞癌、鼻咽癌、口咽癌或喉癌;进一步的所述肿瘤为急性髓系白血病、黑色素瘤、甲状腺癌、结直肠癌、食道癌、肝细胞癌、卵巢癌、纤维肉瘤和胆管癌。
- 如权利要求10所述的方法,其特征在于,所述第二治疗剂选自化疗剂、靶向治疗剂和免疫治疗剂中的一种或几种。
- 如权利要求10所述的方法,其特征在于,所述第二治疗剂选自尼莫司汀、卡莫司汀、洛莫司汀、替莫唑胺、环磷酰胺、异环磷酰胺、甘磷酰芥、去氧氟鸟苷、多西氟鸟啶、氟尿嘧啶、巯嘌呤、巯唑嘌呤、巯鸟嘌呤、氟鸟苷、替加氟、吉西他滨、地西他滨、卡莫氟、羟基脲、甲胺喋呤、优氟定、卡培他滨、安西他滨、塞替哌、放线菌素D、阿霉素、脂质体阿霉素、柔红霉素、表柔比 星、细裂霉素、平阳霉素、吡柔比星、戊柔比星、伊达比星、伊立替康、三尖衫酯碱、喜树碱、羟基喜树碱、托泊替康、长春瑞宾诺维本、紫杉醇、泰索帝、拓扑替康、长春碱、长春新碱、长春地辛、长春酰胺、长春花碱、替尼泊苷、依托泊苷、揽香烯、阿他美坦、阿那曲唑、氨鲁米特、来曲唑、福美坦、甲他孕酮、他莫昔芬、门冬酰胺酚、卡铂、顺铂、达卡巴嗪、奥沙利铂、乐沙定、可铂奥沙、米托蒽醌、丙卡巴肼、多西他赛、吉非替尼、厄洛替尼、埃克替尼、阿法替尼、奥希替尼、克唑替尼、色瑞替尼、艾乐替尼、拉帕替尼、依维莫司、帕博西尼、瑞博西尼、阿帕替尼、瑞戈非尼、索拉菲尼、舒尼替尼、替西罗莫司、乐伐替尼、帕唑替尼、阿雷替尼、阿希替尼、卡博替尼、曲美替尼、比美替尼、维罗非尼、达拉非尼、卡比替尼、凡德他尼、硼替佐米、帕布昔利布、来那度胺、伊沙佐米、伊马替尼、达沙替尼、博舒替尼、帕纳替尼、伊布替尼、艾代拉利司、贝利司他、罗米地辛、伏立诺他、奥拉帕尼、尼拉帕利、狄诺赛麦、维莫德吉、索尼德吉、鲁卡帕尼、布加替尼、比卡鲁胺、恩杂鲁胺、阿比特龙、阿贝西尼、阿帕他胺、阿柏西普、阿扎胞苷、博莱霉素、苯丁酸氮芥、阿糖胞苷、天冬酰胺酶、埃坡霉素、氟达拉滨、氟他胺、双氯乙基甲胺、帕利他塞、培美曲塞、雷替曲塞、耐昔妥珠单抗、贝伐珠单抗、雷莫芦单抗、Ado-曲妥珠单抗、帕托珠单抗、西妥昔单抗、帕尼单抗、阿利库单抗、德瓦鲁单抗、尼妥珠单抗、达雷木单抗、阿特珠单抗、信迪利单抗、特瑞普利单抗、卡瑞利珠单抗、替雷利珠单抗、德瓦鲁单抗、纳武利尤单抗、帕博利珠单抗中的一种或几种;进一步的选自地西他滨、吉西他滨、顺铂、卡铂、奥沙利铂、阿霉素、脂质体阿霉素、紫杉醇、多西他赛、曲美替尼、比美替尼、考比替尼、德瓦鲁单抗、阿特珠单抗、信迪利单抗、特瑞普利单抗、卡瑞利珠单抗、替雷利珠单抗、纳武利尤单抗、帕博利珠单抗;更进一步的选自多西他赛、脂质体阿霉素、考比替尼、帕博利珠单抗、地西他滨;更进一步的选自考比替尼。
- 如权利要求10所述的方法,其特征在于,所述FAK抑制剂和所述第二治疗剂同步、交替或序贯给药。
- 如权利要求11所述的方法,其特征在于,所述FAK抑制剂和放疗或细胞治疗同步、交替或序贯进行。
- 用于治疗NRAS突变的肿瘤的FAK抑制剂。
- 如权利要求17所述的FAK抑制剂,其特征在于,所述FAK抑制剂为BI853520、defactinib、GSK2256098、PF-00562271、VS-4718或其药学上可接受的盐,优选为BI853520或其药学上可接受的盐,尤其是BI853520酒石酸盐。
- 如权利要求17-18中任一项所述的FAK抑制剂,其特征在于,其进一步和有效量的第二治疗剂联用。
- 如权利要求17-19中任一项所述的FAK抑制剂,其特征在于,其进一步与放疗或者细胞治疗联用。
- 如权利要求17所述的FAK抑制剂,其特征在于,所述肿瘤为为霍奇金淋巴瘤、非霍奇金淋巴瘤、非小细胞肺癌、小细胞肺癌、肝细胞癌、胆管癌、骨髓增生异常综合征、急性淋巴细胞白血病、急性髓系白血病、慢性髓系白血病、甲状腺癌、神经胶质瘤、结肠癌、直肠癌、结直肠癌、卵巢癌、膀胱癌、前列腺癌、乳腺癌、脂肪肉瘤、纤维肉瘤、横纹肌肉瘤、平滑肌肉瘤、血管肉瘤、神经母细胞瘤、肾细胞癌、头颈部癌、胃癌、食管癌、胃食管结合部癌、胸腺癌、胰腺癌、子宫内膜癌、宫颈癌、黑色素瘤、皮肤癌、生殖细胞癌、鼻咽癌、口咽癌、或喉癌;进一步的所述肿瘤为急性髓系白血病、黑色素瘤、甲状腺癌、结直肠癌、食道癌、肝细胞癌、卵巢癌、纤维肉瘤和胆管癌。
- 如权利要求19所述的FAK抑制剂,其特征在于,第二治疗剂选自化疗剂、靶向治疗剂和免疫治疗剂中的一种或几种。
- 如权利要求19所述的FAK抑制剂,其特征在于,所述第二治疗剂选自尼莫司汀、卡莫司汀、洛莫司汀、替莫唑胺、环磷酰胺、异环磷酰胺、甘磷酰芥、去氧氟鸟苷、多西氟鸟啶、氟尿嘧啶、巯嘌呤、巯唑嘌呤、巯鸟嘌呤、氟鸟苷、替加氟、吉西他滨、地西他滨、卡莫氟、羟基脲、甲胺喋呤、优氟定、卡培他滨、安西他滨、塞替哌、放线菌素D、阿霉素、脂质体阿霉素、柔红霉素、表柔比星、细裂霉素、平阳霉素、吡柔比星、戊柔比星、伊达比星、伊立替康、三尖衫酯碱、喜树碱、羟基喜树碱、托泊替康、长春瑞宾诺维本、紫杉醇、泰索帝、拓扑替康、长春碱、长春新碱、长春地辛、长春酰胺、长春花碱、替尼泊苷、依托泊苷、揽香烯、阿他美坦、阿那曲唑、氨鲁米特、来曲唑、福美坦、甲他孕酮、他莫昔芬、门冬酰胺酚、卡铂、顺铂、达卡巴嗪、奥沙利铂、乐沙定、可铂奥沙、米托蒽醌、丙卡巴肼、多西他赛、吉非替尼、厄洛替尼、埃克替尼、阿法替尼、奥希替尼、克唑替尼、色瑞替尼、艾乐替尼、拉帕替尼、依维莫司、帕博西尼、瑞博西尼、阿帕替尼、瑞戈非尼、索拉菲尼、舒尼替尼、替西罗莫司、乐伐替尼、帕唑替尼、阿雷替尼、阿希替尼、卡博替尼、曲美替尼、比美替尼、维罗非尼、达拉非尼、卡比替尼、凡德他尼、硼替佐米、帕布昔利布、来那度胺、伊沙佐米、伊马替尼、达沙替尼、博舒替尼、帕纳替尼、伊布替尼、艾代拉利司、贝利司他、罗米地辛、伏立诺他、奥拉帕尼、尼拉帕利、狄诺赛麦、维莫德吉、索尼德吉、鲁卡帕尼、布加替尼、比卡鲁胺、恩杂鲁胺、阿比特龙、阿贝西尼、阿帕他胺、阿柏西普、阿扎胞苷、博莱霉素、苯丁酸氮芥、阿糖胞苷、天冬酰胺酶、埃坡霉素、氟达拉滨、氟他胺、双氯乙基甲胺、帕利他塞、培美曲塞、雷替曲塞、耐昔妥珠单抗、贝伐珠单抗、雷莫芦单抗、Ado-曲妥珠单抗、帕托珠单抗、西妥昔单抗、帕尼单抗、阿利库单抗、德瓦鲁单抗、尼妥珠单抗、达雷木单抗、阿特珠单抗、 信迪利单抗、特瑞普利单抗、卡瑞利珠单抗、替雷利珠单抗、德瓦鲁单抗、纳武利尤单抗、帕博利珠单抗中的一种或几种;进一步的选自地西他滨、吉西他滨、顺铂、卡铂、奥沙利铂、阿霉素、脂质体阿霉素、紫杉醇、多西他赛、曲美替尼、比美替尼、考比替尼、德瓦鲁单抗、阿特珠单抗、信迪利单抗、特瑞普利单抗、卡瑞利珠单抗、替雷利珠单抗、纳武利尤单抗、帕博利珠单抗;更进一步的选自多西他赛、脂质体阿霉素、考比替尼、帕博利珠单抗、地西他滨;更进一步的选自考比替尼。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PE2022000810A PE20221259A1 (es) | 2019-11-18 | 2020-11-17 | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras |
KR1020227020144A KR20220101677A (ko) | 2019-11-18 | 2020-11-17 | Nras 돌연변이를 갖는 종양을 치료하기 위한 약물의 제조에서의 fak 억제제의 용도 |
EP20890277.5A EP4062914A4 (en) | 2019-11-18 | 2020-11-17 | USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION |
JP2022529446A JP2023503897A (ja) | 2019-11-18 | 2020-11-17 | Nras変異を有する腫瘍を治療するための医薬品の調製におけるfak阻害剤の使用 |
US17/777,769 US20230145356A1 (en) | 2019-11-18 | 2020-11-17 | Use of fak inhibitor in preparation of drug for treating tumors having nras mutation |
BR112022009571A BR112022009571A2 (pt) | 2019-11-18 | 2020-11-17 | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras |
CN202080078892.0A CN114667144A (zh) | 2019-11-18 | 2020-11-17 | Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 |
AU2020388848A AU2020388848A1 (en) | 2019-11-18 | 2020-11-17 | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation |
MX2022005994A MX2022005994A (es) | 2019-11-18 | 2020-11-17 | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras. |
CA3158585A CA3158585A1 (en) | 2019-11-18 | 2020-11-17 | Use of fak inhibitor in preparation of drug for treating tumors having nras mutation |
US18/350,303 US20230364088A1 (en) | 2019-11-18 | 2023-07-11 | Use of fak inhibitor in preparation of drug for treating tumors having nras mutation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911128794.9 | 2019-11-18 | ||
CN201911128794 | 2019-11-18 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/777,769 A-371-Of-International US20230145356A1 (en) | 2019-11-18 | 2020-11-17 | Use of fak inhibitor in preparation of drug for treating tumors having nras mutation |
US18/350,303 Continuation US20230364088A1 (en) | 2019-11-18 | 2023-07-11 | Use of fak inhibitor in preparation of drug for treating tumors having nras mutation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021098679A1 true WO2021098679A1 (zh) | 2021-05-27 |
Family
ID=75981319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/129350 WO2021098679A1 (zh) | 2019-11-18 | 2020-11-17 | Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20230145356A1 (zh) |
EP (1) | EP4062914A4 (zh) |
JP (1) | JP2023503897A (zh) |
KR (1) | KR20220101677A (zh) |
CN (1) | CN114667144A (zh) |
AU (1) | AU2020388848A1 (zh) |
BR (1) | BR112022009571A2 (zh) |
CA (1) | CA3158585A1 (zh) |
MX (1) | MX2022005994A (zh) |
PE (1) | PE20221259A1 (zh) |
WO (1) | WO2021098679A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113855695A (zh) * | 2021-11-01 | 2021-12-31 | 上海理工大学 | 一种结肠释药口服复方药物组合物及其制备方法 |
WO2022028367A1 (zh) * | 2020-08-03 | 2022-02-10 | 应世生物科技(南京)有限公司 | 化合物的固体形式 |
CN114681471A (zh) * | 2022-01-19 | 2022-07-01 | 杭州师范大学 | 一种硼替佐米和榄香烯分子配伍药物组合及其应用 |
WO2023138630A1 (zh) * | 2022-01-21 | 2023-07-27 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
WO2023193705A1 (zh) * | 2022-04-07 | 2023-10-12 | 深圳微芯生物科技股份有限公司 | 西奥罗尼在抗胰腺癌中的用途 |
WO2023246869A1 (zh) * | 2022-06-24 | 2023-12-28 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
WO2024051679A1 (zh) * | 2022-09-05 | 2024-03-14 | 应世生物科技(南京)有限公司 | Fak抑制剂及egfr-tki的药物组合及用途 |
US11999719B2 (en) | 2020-08-03 | 2024-06-04 | Inxmed (Nanjing) Co., Ltd. | Solid form of compound |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021104454A1 (zh) * | 2019-11-28 | 2021-06-03 | 应世生物科技(南京)有限公司 | Bi853520在癌症治疗中的用途 |
CN115052603B (zh) * | 2020-02-05 | 2023-12-19 | 应世生物科技(南京)有限公司 | Bi853520与化疗药物的联用 |
WO2023104151A1 (zh) * | 2021-12-10 | 2023-06-15 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
CN117582504A (zh) * | 2022-08-15 | 2024-02-23 | 海创药业股份有限公司 | 一种治疗卵巢癌的联合用药物 |
WO2024041527A1 (zh) * | 2022-08-24 | 2024-02-29 | 应世生物科技(南京)有限公司 | Fak抑制剂及微管抑制剂的药物组合及用途 |
WO2024067631A1 (zh) * | 2022-09-30 | 2024-04-04 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058032A2 (en) | 2008-11-24 | 2010-05-27 | Boehringer Ingelheim International Gmbh | New compounds |
CN108289892A (zh) * | 2015-06-29 | 2018-07-17 | 维瑞斯特姆股份有限公司 | 治疗组合物、组合和使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3102232B1 (en) * | 2014-02-07 | 2020-02-05 | Verastem, Inc. | Methods and compositions for treating abnormal cell growth |
JP2022547358A (ja) * | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
CN115052603B (zh) * | 2020-02-05 | 2023-12-19 | 应世生物科技(南京)有限公司 | Bi853520与化疗药物的联用 |
-
2020
- 2020-11-17 JP JP2022529446A patent/JP2023503897A/ja active Pending
- 2020-11-17 CA CA3158585A patent/CA3158585A1/en active Pending
- 2020-11-17 US US17/777,769 patent/US20230145356A1/en active Pending
- 2020-11-17 BR BR112022009571A patent/BR112022009571A2/pt unknown
- 2020-11-17 AU AU2020388848A patent/AU2020388848A1/en active Pending
- 2020-11-17 MX MX2022005994A patent/MX2022005994A/es unknown
- 2020-11-17 CN CN202080078892.0A patent/CN114667144A/zh active Pending
- 2020-11-17 KR KR1020227020144A patent/KR20220101677A/ko active Search and Examination
- 2020-11-17 EP EP20890277.5A patent/EP4062914A4/en active Pending
- 2020-11-17 PE PE2022000810A patent/PE20221259A1/es unknown
- 2020-11-17 WO PCT/CN2020/129350 patent/WO2021098679A1/zh unknown
-
2023
- 2023-07-11 US US18/350,303 patent/US20230364088A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058032A2 (en) | 2008-11-24 | 2010-05-27 | Boehringer Ingelheim International Gmbh | New compounds |
CN102292322A (zh) * | 2008-11-24 | 2011-12-21 | 贝林格尔.英格海姆国际有限公司 | 用于治疗例如癌症的疾病的取代的嘧啶 |
CN108289892A (zh) * | 2015-06-29 | 2018-07-17 | 维瑞斯特姆股份有限公司 | 治疗组合物、组合和使用方法 |
Non-Patent Citations (10)
Title |
---|
CUIFFO BREN R: "Palmitoylation of oncogenic NRAS is essential for leukemogenesis", BLOOD, vol. 115, 2010, pages 3598 - 605, XP055064320, DOI: 10.1182/blood-2009-03-213876 |
FREDERICKS JREN R: "The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia", FRONT MED CHINA, vol. 7, 2013, pages 452 - 61 |
LEE BRIAN Y.; TIMPSON PAUL; HORVATH LISA G.; DALY ROGER J.: "FAK Signaling in Human Cancer As a Target for Therapeutics.", PHARMACOLOGY & THERAPEUTICS, vol. 146, 12 October 2014 (2014-10-12), pages 132 - 149, XP029132964, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2014.10.001 * |
PARIKH CSUBRAHMANYAM RREN R: "Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice", CANCER RES., vol. 67, 2007, pages 7139 - 46 |
See also references of EP4062914A4 |
TIEDE STEFANIE, MEYER-SCHALLER NATHALIE, KALATHUR RAVI KIRAN REDDY, IVANEK ROBERT, FAGIANI ERNESTA, SCHMASSMANN PHILIP, STILLHARD : "The FAK Inhibitor BI 853520 Exerts Anti-tumor Effects in Breast Cancer", ONCOGENESIS, vol. 7, no. 9, 73, 20 September 2018 (2018-09-20), pages 1 - 19, XP055813573, ISSN: 2157-9024, DOI: 10.1038/s41389-018-0083-1 * |
ULRICH A. HIRT, IRENE C. WAIZENEGGER, NORBERT SCHWEIFER, CHRISTIAN HASLINGER, DANIEL GERLACH, JÜRGEN BRAUNGER, ULRIKE WEYER-CZERNI: "Efficacy of the Highly Selective Focal Adhesion Kinase Inhibitor BI 853520 in Adenocarcinoma xenograft Models Is Linked To a Mesenchymal Tumor Phenotype.", ONCOGENESIS, vol. 7, no. 2, 21, 23 February 2018 (2018-02-23), pages 1 - 11, XP055813570, ISSN: 2157-9024, DOI: 10.1038/s41389-018-0032-z * |
ZHANG HAO, SHAO HUANJIE, GOLUBOVSKAYA VITA M, CHEN HONGBIN, CANCE WILLIAM, ADJEI ALEX A, DY GRACE K: "Efficacy of Focal Adhesion Kinase Inhibition in Non-small Cell Lung Cancer With Oncogenically Activated MAPK Pathways.", BRITISH JOURNAL OF CANCER, vol. 115, no. 2, 23 June 2016 (2016-06-23), pages 203 - 211, XP055813565, ISSN: 1532-1827, DOI: 10.1038/bjc.2016.190 * |
ZHANG JHCHUNG TDYOLDENBURG KR: "A simple statistical parameter for use in evaluation and validation of high throughput screening assays", JBIOMOL SCREEN, vol. 4, 1999, pages 67 - 73, XP001145867, DOI: 10.1177/108705719900400206 |
ZHANG XREN R: "Bcr-abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia", BLOOD, vol. 92, 1998, pages 3829 - 40 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022028367A1 (zh) * | 2020-08-03 | 2022-02-10 | 应世生物科技(南京)有限公司 | 化合物的固体形式 |
US11999719B2 (en) | 2020-08-03 | 2024-06-04 | Inxmed (Nanjing) Co., Ltd. | Solid form of compound |
CN113855695A (zh) * | 2021-11-01 | 2021-12-31 | 上海理工大学 | 一种结肠释药口服复方药物组合物及其制备方法 |
CN114681471A (zh) * | 2022-01-19 | 2022-07-01 | 杭州师范大学 | 一种硼替佐米和榄香烯分子配伍药物组合及其应用 |
CN114681471B (zh) * | 2022-01-19 | 2023-06-06 | 杭州师范大学 | 一种硼替佐米和榄香烯分子配伍药物组合及其应用 |
WO2023138630A1 (zh) * | 2022-01-21 | 2023-07-27 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
WO2023193705A1 (zh) * | 2022-04-07 | 2023-10-12 | 深圳微芯生物科技股份有限公司 | 西奥罗尼在抗胰腺癌中的用途 |
WO2023246869A1 (zh) * | 2022-06-24 | 2023-12-28 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
US11986477B2 (en) | 2022-06-24 | 2024-05-21 | Inxmed (Nanjing) Co., Ltd. | Drug combination and use for treating tumors |
WO2024051679A1 (zh) * | 2022-09-05 | 2024-03-14 | 应世生物科技(南京)有限公司 | Fak抑制剂及egfr-tki的药物组合及用途 |
Also Published As
Publication number | Publication date |
---|---|
US20230145356A1 (en) | 2023-05-11 |
EP4062914A4 (en) | 2024-01-17 |
KR20220101677A (ko) | 2022-07-19 |
BR112022009571A2 (pt) | 2022-08-02 |
CA3158585A1 (en) | 2021-05-27 |
US20230364088A1 (en) | 2023-11-16 |
EP4062914A1 (en) | 2022-09-28 |
CN114667144A (zh) | 2022-06-24 |
MX2022005994A (es) | 2022-06-17 |
JP2023503897A (ja) | 2023-02-01 |
AU2020388848A1 (en) | 2022-05-26 |
PE20221259A1 (es) | 2022-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021098679A1 (zh) | Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 | |
Caffo et al. | Innovative therapeutic strategies in the treatment of brain metastases | |
Ling et al. | An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer | |
JP2021521247A (ja) | 腫瘍療法の副作用の予防または治療方法 | |
Chen et al. | Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts | |
Babar et al. | Targeting the tumor microenvironment: Potential strategy for cancer therapeutics | |
CN104661678A (zh) | 包含双重血管生成素-2/Dll4结合物和抗VEGF-R药剂的药物组合 | |
CA3222772A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
US20180207184A1 (en) | Methods for treating chemoresistant cancer-initiating cells | |
US11466054B2 (en) | Inhibitors of metastasis | |
Büchler et al. | Combination therapy for advanced pancreatic cancer using Herceptin™ plus chemotherapy | |
US20190336599A1 (en) | Combination of ramucirumab and merestinib for use in treatment of colorectal cancer | |
US20180207268A1 (en) | Combination therapy for cancer | |
JP7303205B2 (ja) | 胆道癌を処置するための方法および併用療法 | |
JP2009509974A (ja) | 抗癌治療 | |
WO2010109706A1 (ja) | 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 | |
TWI670079B (zh) | 用於對抗具抗藥性癌症之組合物及方法 | |
US20230338297A1 (en) | Encapsulated Agents that Bind to MCT-1 | |
CA3231639A1 (en) | Triple-agent therapy for cancer treatment | |
CN118159262A (zh) | 用于癌症治疗的三剂疗法 | |
Ngwa | Targeting Vascular Endothelial Glutaminase in Triple Negative Breast Cancer | |
TW202139992A (zh) | 用於癌症治療之醫藥組合 | |
Rincon-Torroella et al. | ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 | |
CN117897158A (zh) | Erk1/2和shp2抑制剂组合疗法 | |
WO2022271939A1 (en) | Erk1/2 and cdk4/6 inhibitors combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20890277 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3158585 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022529446 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022009571 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020388848 Country of ref document: AU Date of ref document: 20201117 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227020144 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020890277 Country of ref document: EP Effective date: 20220620 |
|
ENP | Entry into the national phase |
Ref document number: 112022009571 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220517 |